At a glance

What is MOTS-c?

MOTS-c is a naturally occurring 16-amino acid peptide encoded within the mitochondria, the cell's energy structures. It has drawn research interest as a possible "exercise mimetic" for metabolic health. It is sold through wellness and "research peptide" channels, and it is not an approved medicine.

How does it work?

MOTS-c is proposed to move into the cell nucleus under metabolic stress and influence genes that regulate metabolism, including the AMPK energy-sensing pathway, improving muscle glucose handling and insulin sensitivity. Its blood levels reportedly decline with age and rise after intense exercise. In mice, MOTS-c improved exercise capacity and metabolic markers. These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit in people.

Is it FDA-approved?

No. MOTS-c is not approved by the FDA. In July 2026 the FDA's Pharmacy Compounding Advisory Committee gave MOTS-c a non-binding favorable vote toward the 503A compounding list. Because that vote is only a recommendation and the FDA has not completed rulemaking, MOTS-c is not currently on the list and cannot be legally compounded by U.S. pharmacies on that basis.

What does the research show?

The evidence is largely preclinical:

Its marketed benefit is therefore unproven in people.

Frequently asked questions

What is MOTS-c and what does it do?

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, identified in a 2015 paper by Lee and colleagues in Cell Metabolism. In cell culture and mouse models, it activates AMPK through folate-cycle pathway inhibition, increases GLUT4 expression and glucose uptake³ in skeletal muscle, and translocates to the nucleus during metabolic stress to regulate antioxidant response genes. In humans, endogenous MOTS-c rises substantially with exercise. Whether injectable MOTS-c produces equivalent biological effects in humans has not been established in controlled clinical trials.

Is MOTS-c a mitochondrial peptide?

Yes. MOTS-c is encoded within the 12S ribosomal RNA gene³ of the mitochondrial genome , making it part of a family of molecules called mitochondrial-derived peptides (MDPs). This is a biologically unusual feature: most circulating signaling peptides are encoded in the nuclear genome. The mitochondrial origin of MOTS-c is central to its proposed biology as a retrograde stress signal that communicates mitochondrial metabolic state to the nucleus and other tissues.

Is MOTS-c FDA-approved?

No. As of September 2026, MOTS-c is not FDA-approved for any indication. It is not legally marketed for human therapeutic use in the United States. There is no completed Phase 2 or Phase 3 human efficacy trial in the published literature. Products sold online as injectable MOTS-c are not regulated for quality, purity, or sterility.

Is MOTS-c legal in the United States?

MOTS-c is not FDA-approved and is not legally marketed as a therapeutic product. As of September 2026, it is not on the FDA's 503A bulks list or in Category 1, and FDA removed it from Category 2⁴ in April 2026, so no approved compounding pathway exists. Products sourced from online vendors are sold as research chemicals and fall outside pharmaceutical regulatory oversight. For competitive athletes, MOTS-c is explicitly prohibited at all times under the 2026 WADA Prohibited List⁵ (Section S4.4.1, AMPK activators).

What does the research show about MOTS-c and exercise physiology?

In mouse models, MOTS-c injections increased running capacity; the Reynolds et al. 2021 Nature Communications study reported improved physical capacity metrics in late-life rodent dosing experiments. In humans, endogenous MOTS-c in skeletal muscle rises approximately 12-fold⁶ with an acute bout of exercise, consistent with a role as an exercise-response signaling molecule. Whether exogenous MOTS-c administration replicates these preclinical findings in humans has not been tested in any published controlled human trial.

What are the side effects of MOTS-c?

No peer-reviewed human safety data exists, and FDA has identified no human exposure data⁴ for drug products containing MOTS-c. Long-term safety in humans is entirely unknown.

Can a doctor prescribe MOTS-c?

No. MOTS-c is not FDA-approved for any indication and does not have a legal compounding pathway under 503A as of September 2026. It cannot be prescribed and dispensed through a licensed pharmacy. Any product sold as MOTS-c exists outside the regulated pharmaceutical system.

What is the difference between MOTS-c and humanin?

Both are mitochondrial-derived peptides encoded in the mitochondrial genome, but in different regions: MOTS-c is encoded in the 12S rRNA gene, while humanin is encoded in the 16S rRNA gene. Their proposed mechanisms differ as well , MOTS-c is primarily studied for metabolic and exercise-related effects through AMPK activation, while humanin has been more extensively studied for neuroprotective and cytoprotective effects. Both show age-related changes in circulating levels, and both belong to the MDP family described in the 2022 Miller et al. review⁷ in the Journal of Clinical Investigation. This comparison is for scientific context only; neither compound is FDA-approved for human therapeutic use.

More for hormones & metabolism